Press Releases

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on June 14,...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that the United States Court of Appeals for the fourth Circuit has affirmed an earlier decision...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its third quarter fiscal 2011 on Tuesday, May 3, 2011...

Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to...

Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Barclays Capital 2011 Global...

Perrigo (Nasdaq: PRGO;TASE) today announced that, as part of the anticipated follow-up to the warning letter Perrigo received on April 30, 2010, the...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi 2011 Global Health Care...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for calcipotriene 0.005% and betamethasone...

Perrigo (Nasdaq: PRGO; TASE) today announced that it has begun selling OTC infant formula to Costco in Canada. The product will be sold under Costco's...

Perrigo (Nasdaq: PRGO; TASE) today announced that it has entered into an exclusive agreement with AgaMatrix, Inc. to sell and distribute blood glucose...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has agreed to settle its Hatch-Waxman litigation relating to Minoxidil foam brought by...

-- Fiscal second quarter revenue from continuing operations increased $135 million, or 23%, to $718 million -- Fiscal second quarter GAAP income from...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on March...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of Paddock...

Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its second quarter fiscal 2011 on Tuesday, February 1,...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 29th Annual J.P. Morgan...

IR Global Rankings ("IRGR"), the most comprehensive technical ranking system for investor relations websites, corporate governance practices and...

JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 12/10/10 -- www.stockcall.com/ offers investors comprehensive research on the drug related products industry and has completed analytical research on...

In the news release, Perrigo Announces Launch of Naproxen Sodium Soft Gels - Generic Equivalent to Aleve® Liquid Gels, issued 29-Nov-2010 by Perrigo over PR Newswire, we are advised by the...

Perrigo (Nasdaq: PRGO;TASE) today announced that its licensor and supplier Synthon has received final approval from the U.S. Food and Drug...

Perrigo (Nasdaq: PRGO; TASE) today announced that it has launched Naproxen Sodium Soft Gels. The product is the generic equivalent of Bayer...

IR Global Rankings (IRGR) is pleased to announce that it will collaborate with Institutional Investor magazine on a series of Investor Relations events...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse Annual...

JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 11/09/10 -- www.wallstreetequityresearch.com brings investors market knowledge on the aspects moving the drug related products stocks, and offers...

Fiscal first quarter revenue from continuing operations increased $113 million, or 21 percent, to a record $641 million Fiscal first quarter...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.07 per share, payable on...

Perrigo Company (Nasdaq: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal 2011 on Tuesday, November...

Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically...

JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 09/02/10 -- www.wallstreetequityresearch.com gives shareholders valuable insight on drug related products stocks Perrigo Co. (NASDAQ: PRGO) and NBTY...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced it received FDA clearance on August 23, 2010 to manufacture infant formula liquid concentrate and ready-to-use products through its partner...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for clobetasol propionate shampoo,...

-- Full-year revenue from continuing operations increased $262 million, or 13 percent, to a record $2.27 billion. -- Adjusted income from continuing operations for the full year increased 50...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on September 14, 2010 to shareholders of record...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for butoconazole nitrate vaginal...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2010 on Thursday, August 12, 2010 at approximately 8:00 a.m. (ET). The Company...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC)...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced its filing with the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Emulsion...

Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute OTC versions of Fexofenadine HCl 180 mg and 60 mg tabs, plus...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Oppenheimer 10th Annual Consumer, Gaming, Lodging & Leisure Conference...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Executive Vice President and CFO Judy Brown will present at the 31st Annual Goldman Sachs Global Healthcare Conference on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced on May 26, 2010 that it had acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the Citi Investment Research Global Health Care Conference on Wednesday, May...

Perrigo (NASDAQ: PRGO)( TASE: PRGO) today announced that it has acquired the exclusive U.S. store brand rights to sell and distribute Dextromehtorphan Polistirex Extended Release Suspension Cough...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has closed the previously announced acquisition of PBM Holdings, Inc., the world's largest manufacturer of infant formula for...

-- Fiscal third quarter revenue from continuing operations increased $32 million, or 6%, to $538 million -- Fiscal third quarter adjusted income from continuing operations increased 49% to $70...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on June 15, 2010 to shareholders of record on May...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2010 on Thursday, April 29, 2010 at approximately 8:00 a.m. (ET). The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has been named as an authorized generic partner by Ferndale Laboratories and has launched an authorized generic of Analpram HC®...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) and Graceway Pharmaceuticals, LLC., (based in Bristol, TN) today announced that they have entered into an agreement to settle all existing patent...

Perrigo Company of South Carolina, Inc. (NASDAQ: PRGO)(TASE: PRGO) announced today that it won two favorable jury verdicts against Rexall Sundown, Inc. in an unfair competition lawsuit that was...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that, together with its partner Cobrek Pharmaceuticals, Inc., it has agreed to settle all Hatch-Waxman litigation relating to...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that together with its partner Cobrek Pharmaceuticals, Inc. final approval has been received from the U.S. Food and Drug Administration...

-- PBM Holdings is the world's largest manufacturer and marketer of infant formulas for the store brand market -- All cash transaction with a purchase price of $808 million -- Acquisition expected...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has begun shipping Ketotifen Fumarate ophthalmic solution, 0.025%, a generic version of Zaditor™. Zaditor™ is a sterile...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has signed a definitive purchase agreement to acquire Orion Laboratories Pty, Ltd. for approximately $48 million in cash. Based...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Shampoo, 1%, a...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that a federal court has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600...

-- Fiscal second quarter revenue from continuing operations increased $46 million, or 9%, to $583 million -- Fiscal second quarter adjusted income from continuing operations increased 56% to $65...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on March 16, 2010 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2010 on Tuesday, February 2, 2010 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for Clobetasol Propionate Topical Spray, 0.05%, a generic form of Clobex® Spray....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced it will implement a labeling program to help consumers more clearly identify more than 200 of the company's over-the-counter store-brand...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Sidoti Emerging Growth Conference on Friday, November 20, at 3:15 p.m....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...

-- Fiscal first quarter revenue from continuing operations increased $72 million, or 16%, to $528 million -- Fiscal first quarter GAAP income from continuing operations increased 59% to $61...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has signed a definitive agreement to sell its Israel Consumer Products business along with the related production assets in...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on December 15, 2009 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 a.m. (ET). The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Duac® Gel (clindamycin phosphate (1%) and benzoyl peroxide (5%) gel) filed by the Stiefel...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will hold its Investor Day from 8:30 a.m. to approximately 12:00 p.m. EDT on September 29, at the NASDAQ MarketSite located at 4 Times Square in New...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has purchased the ANDA for clindamycin phosphate (1%) and benzoyl peroxide (5%) gel from KV Pharmaceutical for $14 million in...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 27, 2009. Perrigo's Chairman and CEO Joseph C. Papa commented, "Our sales topped...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on September 15, 2009 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2009 on Tuesday, August 18, 2009 at approximately 8:00 a.m. (ET). The Company...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) (previously Barr Laboratories Inc.) has received final approval from...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Synthon Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Levocetirizine solution...

-- Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, to $506 million as compared to $481 million this quarter a year ago -- Fiscal third quarter earnings from...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on June 16, 2009 to shareholders of record on May...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10%...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that has begun shipping over-the-counter (OTC) Ibuprofen and Diphenhydramine Citrate Tablets, 200/38 mg. The product will be marketed...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2009 second quarter and six months that ended December 27, 2008. Perrigo Company (in thousands, except per...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on March 17, 2009 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal year 2009 on Tuesday, February 3, 2009 at approximately 8:00 a.m....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg) has been settled with Perrigo taking a license under all...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today acknowledges the settlement of patent litigation brought by Sanofi-Aventis (NYSE: SNY) against Barr Laboratories, Inc. a subsidiary of Barr...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired Unico Holdings for approximately $49 million in cash. Based in Lake Worth, Florida, privately-held Unico is the...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2009 first quarter that ended September 27, 2008. Perrigo Company (in thousands, except per share amounts)...